View abstract

Cet abstract a été assigné à sessions

Type de présentation	E-poster
Titre	Conjunctival TFG::ROS1 fusion positive inflammatory myofibroblastic tumor treated with crizotinib

But	To describe the clinical course and management of a conjunctival inflammatory myofibroblastic tumor with a TFG::ROS1 fusion in a 33-year-old woman presenting with a progressively enlarging subconjunctival mass.
Méthodes	Diagnosis was confirmed by biopsy and RNA next-generation sequencing.
Résultats	Treatment with the tyrosine kinase inhibitor crizotinib led to complete tumor resolution, however therapy was discontinued due to a sarcoid-like granulomatous reaction. Visual acuity remained stable at 20/20 throughout, and no recurrence was observed.
Conclusion	This case highlights the diagnostic challenges of conjunctival inflammatory myofibroblastic tumor, the therapeutic potential of targeted kinase inhibition, and the critical role of genomic profiling in guiding personalized treatment for rare ocular tumors such as inflammatory myofibroblastic tumor.
Conflit d'intérêt	Non

Auteurs 1

Initiales	L
Nom	Bourdeaud'huy
Institut	Universiteit Gent
Ville	Gent

Auteurs 2

Initiales	D
Nom	Roels
Institut	UZ Gent
Ville	Gent